BCL2L1 is an important anti‐apoptotic gene that is a member of the anti‐apoptotic Bcl‐2 protein family70 and is also a novel oncogenic driver in the progression of GC, which can be used as a potential candidate target for GC therapeutic drugs.71 This evidence concerns the gene BCL2 and gastric cancer.